SmithKline Beecham manager

SmithKline Beecham Clinical Laboratories, 1996-1999 Senior Territory Sales Manager... 

Within the pharmaceutical industry itself, the wish of each company s management to see its firm reach what is considered a critical size remained a constant feature as the century came to an end and the new millennium began. It led to new national and transnational mergers. In France, Sanofi (Elf Aquitaine) merged with Synthelabo (L Oreal) and Laboratoires Pierre Fabre with BioMerieux. Elsewhere the Swedish Astra and the British Zeneca combined their operations Pharmacia-Upjohn took control of Monsanto and two giant firms, Glaxo Wellcome and SmithKline Beecham, announced their intention to combine their activities, which would lead to a group with a turnover of 25 billion, exceeded only by Pfizer after its acquisition of Warner Lambert. 

In 1993 and 1994 Merck, Lilly, and the then SmithKline Beecham all bought PBMs. In addition, Bristol-Myers Squibb had bid against Merck, and Pfizer and Johnson Johnson at one point considered purchasing benefits managers, too. Yet by 1999, Lilly and SmithKline had sold theirs at a loss, and Bristol-Myers, Johnson Johnson and Pfizer never got in. Merck alone seemed to be able to make its PBM, Merck-Medco Managed Care, work. By 2001, its market share was nearly 29 percent by 2002, it handled the prescriptions for 65 million people, or almost one-fourth of all Americans. 

Independent Consultant and Visiting Professor at the Centre for Molecular Design, University of Portsmouth, UK. Formerly Manager, QSAR, SmithKline Beecham Pharmaceuticals... 

John Hayler read chemistry at the University of Exeter and studied for a PhD in organic synthesis at the University of Bath. He joined SmithKline and French (subsequently SmithKline Beecham and GlaxoSmithKline) in 1987 and is currently a manager in the API Chemistry department, part of Product Development and Supply. His scientific interests include the application of green and sustainable principles to the manufacture of pharmaceutically active compounds. 

Richard Heys received his Ph.D. in organic chemistry from Stanford University in 1976 and conducted postdoctoral research in the chemistry department at Yale both involved the synthesis of radiolabeled compounds and their use in elucidation of biosynthetic pathways. His subsequent 29-year career in organic radiochemical synthesis both in the laboratory and as a manager took him to the Radiochemistry Department of Midwest Research Institute (now part of Aptuit, Inc.), Smith Kline French Laboratories/SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and AstraZeneca Pharmaceuticals. Author or coauthor of over 85 publications, 8 patents and a previous conference proceedings volume in the field, organizer of an international symposium on the synthesis of isotopicaUy labeled compound and holder of leadership positions (including president and CFO) in the International Isotope Society for 9 years, he is retired and lives in northwestern Connecticut. 

---